貨號：GS40435

Milatuzumab (also known as hLL1 or IMMU-115) is a humanized monoclonal antibody that targets CD74, the invariant chain associated with major histocompatibility complex class II (MHC-II). CD74 is a transmembrane glycoprotein that functions as a chaperone for MHC-II and also acts as a signaling receptor for the cytokine macrophage migration inhibitory factor (MIF). It is highly expressed on B cells, monocytes, macrophages, and many B?cell malignancies. Milatuzumab was developed as a potential therapy for B?cell non?Hodgkin lymphoma (NHL) and multiple myeloma, with mechanisms including direct signaling?mediated apoptosis and antibody?dependent cellular cytotoxicity (ADCC). It has also been investigated in autoimmune diseases due to CD74's role in immune cell activation.